We are live on ! Find out more
RUBY

Rubius Therapeutics, Inc
RUBY

Delisted

RUBY was delisted on the 6th of March, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of RUBY yet.

RUBY Hedge Fund Activity: Q2 2023 in Review

0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q2 2023, worth a combined $0 — down 100% from $61.3K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of RUBY and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Artal Group, exiting entirely with an estimated $44K sold.

  • 0 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q2 2023, down from 7 in Q1 2023.
  • Funds reported $0 of Rubius Therapeutics, Inc stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Rubius Therapeutics, Inc positions in Q2 2023 and 7 closed out, a net change of -7 holders.
  • The largest Rubius Therapeutics, Inc seller in Q2 2023 was Artal Group, an estimated $44K sold.

Based on aggregated 13F filings for Q2 2023.